Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Raises $2.4M in Private Placement

NEW YORK (GenomeWeb) – Transgenomic said after the close of the market on Wednesday that it raised $2.375 million in gross proceeds from a private placement.

The financing was raised through a syndicate of new and existing institutional and other accredited investors, and funding will be used for general corporate and working capital purposes, including activities supporting Transgenomic's ICE COLD-PCR technology, the company said.

The company's common shares for the private placement were priced at $3.25 per share, which represents a 10 percent premium to Transgenomic's closing share price of $2.95 on Oct. 21. For each share of common stock purchased, the investors will receive a warrant to purchase .5 shares of the company's common stock at an exercise price of $4 per share. In the aggregate Transgenomic issued about 730,000 shares of its stock and 370,000 warrants, it said.

Earlier this year, the firm completed a financing that raised $7 million from affiliates of life sciences investment firm Third Security. Transgenomic's stock moved to the Nasdaq Capital Market in May.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.